United States
Securities and Exchange Commission
Washington, DC 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report: September 8, 2009
Lannett Company, Inc.
(Exact Name of Registrant as Specified in its Charter)
DE |
| 001-31298 |
| 23-0787699 |
(State or other |
| (Commission File Number) |
| (IRS Employer No.) |
9000 State Road, Philadelphia, PA 19136
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (215) 333-9000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o |
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
o |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
o |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
o |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
(c) Appointment of Vice President of Operations
Effective September 8, 2009, Stephen Kovary has been appointed and will assume the duties as the Company’s Vice President of Operations.
Mr. Kovary, 52, has nearly thirty years of experience in the pharmaceutical industry. Prior to joining Lannett, Mr. Kovary was the Vice President, Plant Manager for PF Laboratories, a division of Purdue Pharma, LP, since 2003. Formerly, Mr. Kovary held senior level management level positions at Pliva, Inc, Abbott Laboratories and Parke-Davis.
Mr. Kovary holds a Bachelor of Science in Pharmacy from the Rutgers University Ernest Mario School of Pharmacy and a Masters in Busi ness Administration in Management from Fairleigh Dickenson University. Mr. Kovary is a member of the American and New Jersey Pharmaceutical Associations, the International Society of Pharmaceutical Engineers and the Parenteral Drug Association. Mr. Kovary is a member of the Dean’s Advisory Board and the Alumni Association of the Rutgers University Ernest Mario School of Pharmacy.
Item 9.01 Financial Statements and Exhibits
(d) |
| Exhibits | |
|
|
| |
|
| 99.1 | September 8, 2009 Press Release |
2
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Lannett Company, Inc. | |
| (Registrant) | |
|
| |
| By: | /s/ Arthur Bedrosian |
|
| Arthur Bedrosian |
|
| President and Chief Executive Officer |
Dated: September 10, 2009 |
| |
3
EXHIBIT INDEX
Exhibit: |
| Description |
|
|
|
99.1 |
| September 8, 2009 Press Release |
4